Oral · GLP-1 agonist
XW014
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
0
Recruiting
0
Completed
1
Sites
3
Countries
1
Endpoints
2
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05579314XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) | XW014 Healthy volunteers, Obesity / overweight, Type 2 diabetes | HbA1c 6.5-8.5% | Ph 1 | Completed | 3 | Nov 2024 | — |